Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Irvine UCLA
Dates
study started
completion around
Principal Investigator
by Sarah Larson (ucla)

Description

Summary

The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.

Official Title

MAGNETISMM-3 AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 2 STUDY OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY

Keywords

Multiple Myeloma, Myeloma, relapsed Multiple Myeloma, refractory Multiple Myeloma, PF-06863135, BCMA, bispecific, bispecific antibody, BCMA-CD3 bispecific, Elranatamab, MagnetisMM-3, Plasma Cell Neoplasms, Elranatamab (PF-06863135)

Eligibility

Locations

  • UCLA Hematology/Oncology Clinic
    Los Angeles California 90095 United States
  • UCLA Ronald Reagan Medical Center
    Los Angeles California 90095 United States
  • UC Irvine Health - Chao Family Comprehensive Cancer Center
    Orange California 92868-3201 United States
  • Beverly Hills Cancer Center
    Beverly Hills California 90211 United States

Lead Scientist at University of California Health

  • Sarah Larson (ucla)
    HS Associate Clinical Professor, Medicine. Authored (or co-authored) 20 research publications

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Pfizer
Links
To obtain contact information for a study center near you, click here. Open Science Registry
ID
NCT04649359
Phase
Phase 2 Multiple Myeloma Research Study
Study Type
Interventional
Participants
About 187 people participating
Last Updated